Cytogenetic alterations in prostate cancer [Zytogenetische veranderungen des prostatakarzinoms]

被引:0
|
作者
Sauter G. [1 ,3 ]
Bubendorf L. [1 ]
Moch H. [1 ]
Gasser Th.C. [2 ]
Mihatsch M.J. [1 ]
机构
[1] Institut fur Pathologie, Universitatskliniken, Kantonsspital Basel, CH-4003 Basel
来源
Der Pathologe | 1998年 / 19卷 / 1期
关键词
Cytogenetics; Gene amplification; Polysomy; Prostate cancer;
D O I
10.1007/s002920050256
中图分类号
学科分类号
摘要
Development and progression of tumors is driven by a malfunction of specific genes. Although prostate cancer is one of the most frequent tumors, little is known about the genes involved. Cytogenetic and molecular examinations have shown that chromosomal deletions most frequently involve 7q, 8p, 10q, 13q, 16q, 17p and the Y chromosome. These loci may carry tumor suppressor genes with relevance for prostate cancer. DNA sequence copy number gains were most frequently observed at chromosomes 7, 8q, and 11q. These regions may carry currently unknown oncogenes. There is increasing evidence for a clinical relevance of genetic alterations. Polysomies of several chromosomes were shown to be associated with poor prognosis of prostate cancer patients. Androgen receptor amplification can be found in hormone- refractory carcinomas which may respond to total androgen blockage. For the future it is hoped that the identification of the genes involved in prostate cancer and the determination of their function could allow for significant improvements of treatment strategies for prostate cancer patients.
引用
收藏
页码:63 / 68
页数:5
相关论文
共 50 条
  • [31] Potential of PET/MRI for diagnosis of prostate cancer [Potenziale der PET/MRT in der Diagnostik des Prostatakarzinoms]
    Röthke M.C.
    Afshar-Oromieh A.
    Schlemmer H.-P.
    Der Radiologe, 2013, 53 (8): : 676 - 681
  • [32] Selection criteria for the expected management of localised prostate cancer [Selektionskriterien zum abwartenden management des lokalisierten prostatakarzinoms]
    Graefen M.
    Salomon G.
    Currlin E.
    Eichelberg C.
    Schlomm T.
    Huland H.
    Der Urologe, 2005, 44 (11): : 1277 - 1286
  • [33] Diagnostics and treatment of prostate cancer after kidney transplantation [Diagnostik und therapie des prostatakarzinoms nach nierentransplantation]
    Wicht A.
    Hamza A.
    Loertzer H.
    Dietl M.
    Heynemann H.
    Fornara P.
    Der Urologe, 2006, 45 (1): : 32 - 37
  • [34] Risikoadaptierte Früherkennung des Prostatakarzinoms – Update 2021Risk-adapted prostate cancer screening—update 2021
    R. Al-Monajjed
    C. Arsov
    P Albers
    Der Urologe, 2021, 60 (5): : 592 - 601
  • [35] Active surveillance of localized prostate cancer: Significance of prostate core needle biopsies [Active surveillance des lokalisierten prostatakarzinoms: Wertigkeit der prostatastanzbiopsie]
    Rüschoff J.
    Middel P.
    Albers P.
    Der Pathologe, 2008, 29 (5): : 339 - 347
  • [36] Behandlung des fortgeschrittenen hormonsensitiven Prostatakarzinoms mittels DegarelixTreatment of advanced hormone-sensitive prostate cancer using degarelix
    Nikolaos Pyrgidis
    Georgios Hatzichristodoulou
    Ioannis Sokolakis
    Der Urologe, 2022, 61 (1): : 63 - 67
  • [37] Fokale Therapie des Prostatakarzinoms in Deutschland – Status 2014Focal therapy for prostate cancer in Germany – 2014 status
    A. Roosen
    R. Ganzer
    B. Hadaschik
    J. Köllermann
    A. Blana
    T. Henkel
    A.-B. Liehr
    D. Baumunk
    S. Machtens
    G. Salomon
    L. Sentker
    U. Witsch
    K.U. Köhrmann
    M. Schostak
    Der Urologe, 2014, 53 (7): : 1040 - 1045
  • [38] Genetic and cytogenetic alterations in ovarian cancer
    Bauknecht, T
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 618 - 618
  • [39] Dose to Bone Marrow Using IMRT Techniques in Prostate Cancer PatientsDie Strahlenbelastung des Knochenmarks bei der intensitätsmodulierten Strahlentherapie des Prostatakarzinoms
    Eduard Gershkevitsh
    Catharine H. Clark
    John Staffurth
    David P. Dearnaley
    Klaus-Rüdiger Trott
    Strahlentherapie und Onkologie, 2005, 181 (3) : 172 - 178
  • [40] Bagatellisierung des Prostatakarzinoms?Stadien-Shift und mögliche UrsachenTrivialization of prostate cancer?Stage shift and possible causes
    M. Saar
    M. S. K. M. Abdeen
    C. Niklas
    Z. T. F. Al-Kailani
    S. Siemer
    M. Stöckle
    Der Urologe, 2019, 58 (12): : 1461 - 1468